Alliance for Clinical Trials in Oncology shared a post on X:
“New Trial Alert!
Bradley McGregor from Dana-Farber Cancer Institute leads the Alliance for Clinical Trials in Oncology A032201 (STRIKE) to compare the effect of adding tivozanib to standard therapy pembrolizumab vs pembrolizumab alone to treat patients with high-risk renal cell cancer.”
More posts featuring Alliance for Clinical Trials in Oncology.